1Le Chatelier E, Nielsen T, Qin J, et al. Richness of human gut microbiome correlates with metabolicmarkers [ J ]. Nature, 2013, 500:541-546.
2Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome [ J ]. Nature ,2012 ,486 : 207 -214.
3Gaboriau-Routhiau V, Rakotobe S, Lecuyer E, et al. The key role of segmented filamentous bacteria in the coordinated maturation of gut helper T cell responses [ J ]. Immunity 2009,31:677-689.
4Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients [ J ]. Proc Natl Acad Sci U S A,2008,105,16731-16736.
5Cadwell K, Patel KK, Maloney NS, et al. Virus-plus-susceptibility gene interaction determines Crohn' s disease gene Atgl6L1 phenotypes in intestine[ J]. Cell ,2010,141 : 1135-1145.
6Steed H, Maefarlane GT, Blackett KL, et al. Clinical triM: the microbiological and immunological effects of synbiotic consumption a randomized double-blind placebo-controlled study in active Crohn' s disease [ J ] . Aliment Pharmacol Ther, 2010,32:872-883.
7Schultz M, Timmer A, Herfarth HH, et al. Lactobacillus GG in inducing and maintaining remission of Crohn's disease [ J ]. BMC Gastroenterol, 2004,4 : 5.
8Guslandi M, Mezzi G, Sorghi M, et al. Saccharomyces boulardii in maintenance treatment of Crohn's disease [ J ]. Dig Dis Sci, 2000, 45 : 1462-1464.
9Bousvaros A, Guandalini S, Baldassano RN, et al. A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease [ J]. Inflamm Bowel Dis,2005,11:833-839.
10Marteau P, Lemann M, Seksik P, et al. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn' s disease: a randomised, double blind, placebo controlled GETAID trim [ J ]. Gut,2006,55 : 842-847.
3Martinez-MedinaM, Aldeguer X, Gonzalez-Huix F, et al. Abnor-mal microbiota composition in the ileocolonic mucosa of Crohn ’ sdisease patients as revealed by polymerase chain reaction-denatu-ring gradient gel electrophoresis[J"] . Inflamm Bowel Dis, 2006 ,1 2(12):1136.
8KruisW, Fric P, Pokrotnieks J, Lukas M, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coliNissle 1917 is as effective as with standard mesalazine[J"J. Gut,2004,53:1617.
9Fuller R. Probiotics in man and animals [J ] . J Appl Bacteriol,1989;66:365.
10VanderpoolC, Yan F,Polk DB. Mechanisms of probiotic action:Implications for therapeutic applications in Inflammatory boweldiseases[J] . Inflamm Bowel Dis,2008,14(11) ; 1585.
4Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS. The utility of probiotics in the treatment of ir- ritable bowel syndrome: a systematic review. Am ]Gastroenterol ,2009, 104: 1033-1049, quiz 1050 [PMID: 19277023 DOI: 10.1038/ajg.2009.25].
5Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, Mareya SM, Shaw AL, Bortey E, Forbes WP. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med ,2011,364:22-32 [PMID: 21208106 DOI: 10.1056/NEJ- Moa1004409].
7Martine Z, Medina M, Aldeguer X, et al. Abnormal microbio- ta composition in the ileocolonic mucosa of Crohn's disease pa- tients as revealed by polymerase chain reaction denaturing gra-dient gel electrophoresis[J].Inflamm Bowel Dis, 2006, 12 (12) : 1136-1146.
8Fuller R. Probiotics in man and animals[J]. J Bacteriol, 1989, 66(5) : 365-378.
9Vanderpool C, Yan F, Polk DB. Mechanisms of probiotic action: Implications for therapeutic applications in inflammatory bowel dis- ease[J]. Inflamm Bowel Dis, 2008, 14(11): 1585.
10Kruis W, Fric P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine[J]. Gut, 2004, 53(11): 1617-1623.
